Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04024813 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04024813 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 1 participants.
The verdict
NCT04024813, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).
Interventions
- DRUG Seladelpar
- DRUG Placebo to match Seladelpar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04024813
The ClinicalTrials.gov registry entry for NCT04024813 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Seladelpar is the first listed.
NCT04024813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04024813 about?
NCT04024813 is a clinical study titled "A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC". The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).
What is the current status of trial NCT04024813?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-11-12. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT04024813?
The interventions under investigation include: Seladelpar (DRUG), Placebo to match Seladelpar (DRUG).
Who is sponsoring clinical trial NCT04024813?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.